Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
ICAAC: Study Closes Vicriviroc Story

Merck has halted development of the CCR5 inhibitor vicriviroc for treatment of HIV infection, but the drug may still have a role for pre-exposure prophylaxis or microbicide use.

Published
16 September 2010
From
MedPage Today
GSK new NNRTI selects no resistance mutations in 7 days of monotherapy

GSK2248761, a nonnucleoside (NNRTI) in phase 2 development at GlaxoSmithKline, selected no mutations in reverse transcriptase in 36 antiretroviral-naive people who took the drug as monotherapy for 7 days.

Published
16 September 2010
From
NATAP
K.U.Leuven enters license agreement with Pfizer to commercialize anti-HIV drugs

Pfizer will develop ledgins, which inhibit the interaction between the viral integrase and the cellular protein LEDGF/p75, as a new class of antiretroviral drug.

Published
16 September 2010
From
News-Medical-Net
New NRTI festinavir exhibits good anti-HIV activity and safety in phase 1b/2a study

The new nucleoside reverse transcriptase inhibitor (NRTI) festinavir, or OBP-601, demonstrated good antiviral activity, lowering HIV viral load by more than 1 log over 10 days, researchers reported this week at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) in Boston.

Published
15 September 2010
From
HIVandhepatitis.com
Elvitegravir "Quad" single-tablet regimen shows continued HIV suppression at 48 weeks

Gilead Science's experimental "Quad" pill - a once-daily single-tablet coformulation containing the new integrase inhibitor elvitegravir, the novel boosting agent cobicistat (GS 9350), and tenofovir plus emtricitabine  continued to demonstrate potent antiviral activity and good tolerability at 48 weeks, according to data presented this week at the 50th ICAAC.

Published
15 September 2010
From
HIVandhepatitis.com
Gilead Sciences submits European marketing application for once-daily single-tablet regimen of Truvada(R) and TMC278 for the treatment of HIV infection

The new single-tablet regimen would be only the second product that contains a complete antiretroviral treatment regimen in a single once-daily tablet.

Published
03 September 2010
From
Market Watch
AIDS cure quest to kill `sleeping' viruses enlists Merck cancer medicine

Researchers at the University of North Carolina in Chapel Hill plan to test Merck’s drug, Zolinza, next year in about 20 people infected with HIV,  to determine if Zolinza, or a medicine like it, can force HIV out of cells where it can reside, concealed from attack by potent antiviral treatments.

Published
02 September 2010
From
Bloomberg
Cocktails are next for cancer-drug makers

Big Pharma turns to the multi-drug approach that transformed AIDS.

Published
27 August 2010
From
Bloomberg Business Week
Researchers Identify Two FDA Approved Drugs That May Fight HIV

Researchers at the University of Minnesota Academic Health Center have identified two cancer drugs that, when combined, may cause HIV to mutate to death.

Published
24 August 2010
From
Science Daily
Chimerix's CMX157 Shows Potential to Treat Multi-Drug-Resistant HIV and Improve the Activity and Toxicity Profile of Tenofovir

CMX157 is a new chemical entity created by applying Chimerix's PIM (Phospholipid Intramembrane Microfluidization) Conjugate Technology to chemically modify tenofovir. The technology is designed to improve the absorption and distribution profile of tenofovir.

Published
28 July 2010
From
PR Newswire

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.